Gilead Sciences | GILD - Ebitda

Aktienkurs
128.84
Täglich Wechseln
-0.42 -0.32%
Monatlich
-5.50%
Jährlich
20.93%
Q2 Prognose
127.61




Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
ALKERMES USD 100.31M 21.24M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 1.12B 2.24B 2025-12
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Incyte USD 414.5M 92.42M 2025-12
J&J USD 7.19B 2.32B 2025-12
Merck USD 8.39B 1.97B 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 5.3B 530M 2026-03
Pfizer USD 6.08B 351M 2025-09
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Sanofi EUR 3.31B 3.65B 2026-03
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09